130 related articles for article (PubMed ID: 36728357)
1. Development and Validation of a Quantitative LC-MS/MS Method for CDK4/6 Inhibitors Palbociclib, Ribociclib, Abemaciclib, and Abemaciclib-M2 in Human Plasma.
Burke SM; Kamal M; Goey AKL
Ther Drug Monit; 2023 Jun; 45(3):327-336. PubMed ID: 36728357
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring in breast cancer therapy - LC-MS/MS method for quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, ribociclib, and major metabolites abemaciclib M20 and M2 in human serum.
Habler K; Kalla AS; Rychlik M; Vogeser M; Teupser D
J Pharm Biomed Anal; 2023 Feb; 225():115211. PubMed ID: 36603395
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry.
Martínez-Chávez A; Rosing H; Hillebrand M; Tibben M; Schinkel AH; Beijnen JH
Anal Bioanal Chem; 2019 Aug; 411(20):5331-5345. PubMed ID: 31209549
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of an LC-MS/MS method to measure the BRAF inhibitors dabrafenib and encorafenib quantitatively and four major metabolites semi-quantitatively in human plasma.
Myszkiewicz MF; Puzanov I; Goey AKL
J Pharm Biomed Anal; 2023 Sep; 234():115594. PubMed ID: 37478552
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method.
Posocco B; Zanchetta M; Orleni M; Gagno S; Montico M; Peruzzi E; Roncato R; Gerratana L; Corsetti S; Puglisi F; Toffoli G
Ther Drug Monit; 2024 Feb; ():. PubMed ID: 38366332
[TBL] [Abstract][Full Text] [Related]
6. Establishment of an analytical method for simultaneous quantitation of CDK4/6 inhibitors, aromatase inhibitors, and an estrogen receptor antagonist in human plasma using LC-ESI-MS/MS.
Sato Y; Shigeta K; Hirasawa T; Sato T; Ogura J; Maekawa M; Ebata A; Hamanaka Y; Tada H; Ishida T; Kikuchi M; Mano N
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Mar; 1173():122655. PubMed ID: 33831689
[TBL] [Abstract][Full Text] [Related]
7. Development of a SPE-LC-MS Method for the Quantitation of Palbociclib and Abemaciclib in Human Plasma.
Calucică DM; Manda CV; Găman AM; Răileanu Ș; Stanca L; Popescu MDE; Mateescu OG; Biță A; Croitoru O; Neamțu SD
Molecules; 2022 Dec; 27(23):. PubMed ID: 36500697
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma.
Aghai F; Zimmermann S; Kurlbaum M; Jung P; Pelzer T; Klinker H; Isberner N; Scherf-Clavel O
Anal Bioanal Chem; 2021 Jan; 413(2):599-612. PubMed ID: 33155133
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous quantification of abemaciclib and its active metabolites in human and mouse plasma by UHPLC-MS/MS.
Martínez-Chávez A; Tibben MM; de Jong KAM; Rosing H; Schinkel AH; Beijnen JH
J Pharm Biomed Anal; 2021 Sep; 203():114225. PubMed ID: 34242947
[TBL] [Abstract][Full Text] [Related]
10. Liquid chromatography-tandem mass spectrometric assay for the quantification of CDK4/6 inhibitors in human plasma in a clinical context of drug-drug interaction.
Leenhardt F; Gracia M; Perrin C; Muracciole-Bich C; Marion B; Roques C; Alexandre M; Firmin N; Pouderoux S; Mbatchi L; Gongora C; Jacot W; Evrard A
J Pharm Biomed Anal; 2020 Sep; 188():113438. PubMed ID: 32623316
[TBL] [Abstract][Full Text] [Related]
11. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors.
Burne R; Balu S; Guérin A; Bungay R; Sin R; Paul ML
J Med Econ; 2021; 24(1):806-815. PubMed ID: 34098827
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application.
Posocco B; Buzzo M; Poetto AS; Orleni M; Gagno S; Zanchetta M; Iacuzzi V; Guardascione M; Puglisi F; Basile D; Pelizzari G; Marangon E; Toffoli G
PLoS One; 2020; 15(2):e0228822. PubMed ID: 32032379
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of naltrexone and 6beta-naltrexol in human, rat, and rabbit plasma by liquid chromatography-electrospray ionization tandem mass spectrometry with application to the pharmacokinetics of Depotrex in rabbits.
Slawson MH; Chen M; Moody D; Comer SD; Nuwayser ES; Fang WB; Foltz RL
J Anal Toxicol; 2007 Oct; 31(8):453-61. PubMed ID: 17988459
[TBL] [Abstract][Full Text] [Related]
14. Development and Validation of High-Throughput Bioanalytical Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Method for the Quantification of Newly Synthesized Antitumor Carbonic Anhydrase Inhibitors in Human Plasma.
Abdel-Megied AM; Eldehna WM; Abdelrahman MA; Elbarbry FA
Molecules; 2020 Dec; 25(23):. PubMed ID: 33291270
[TBL] [Abstract][Full Text] [Related]
15. A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer.
Poetto AS; Posocco B; Gagno S; Orleni M; Zanchetta M; Iacuzzi V; Canil G; Buzzo M; Montico M; Guardascione M; Basile D; Pelizzari G; Alberti M; Gerratana L; Puglisi F; Toffoli G
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Nov; 1185():122985. PubMed ID: 34700133
[TBL] [Abstract][Full Text] [Related]
16. Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma/serum using UPLC-MS/MS for therapeutic drug monitoring.
Zhang M; Liu X; Chen Z; Jiang S; Wang L; Tao M; Miao L
J Pharm Biomed Anal; 2022 Mar; 211():114562. PubMed ID: 35124453
[TBL] [Abstract][Full Text] [Related]
17. Validation of an LC-MS/MS assay for rapid and simultaneous quantification of 21 kinase inhibitors in human plasma and serum for therapeutic drug monitoring.
Al Shirity ZN; Westra N; Hateren KV; Munnink THO; Kosterink JGW; Mian P; Hooge MNL; Touw DJ; Gareb B
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Sep; 1229():123872. PubMed ID: 37716342
[TBL] [Abstract][Full Text] [Related]
18. Determination of total and unbound ribociclib in human plasma and brain tumor tissues using liquid chromatography coupled with tandem mass spectrometry.
Bao X; Wu J; Sanai N; Li J
J Pharm Biomed Anal; 2019 Mar; 166():197-204. PubMed ID: 30660034
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous determination of a selective adenosine 2A agonist, BMS-068645, and its acid metabolite in human plasma by liquid chromatography-tandem mass spectrometry--evaluation of the esterase inhibitor, diisopropyl fluorophosphate, in the stabilization of a labile ester-containing drug.
Zeng J; Onthank D; Crane P; Unger S; Zheng N; Pasas-Farmer S; Arnold M
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jun; 852(1-2):77-84. PubMed ID: 17280881
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of LC-MS/MS methods for the quantification of 101BHG-D01, a novel, long-acting and selective muscarinic receptor antagonist, and its main metabolite M6 in human plasma, urine and feces: Application to a clinical study in healthy Chinese subjects.
Gao H; Cheng M; Liu H; Ding L
J Pharm Biomed Anal; 2023 Sep; 233():115498. PubMed ID: 37285657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
